IL17A and psoriasis: Additionally, IMQ stimulates the release of inflammatory factors such as IL-1β, IL-6, IL-23, and IL-17 (Su et al. 2022) leading to produce psoriasis-like symptoms in the skin, including erythema, scaling, and epidermal thickening.